AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
NEOSTIGMINE
6 registrations across 4 African markets— 4 active
Markets with NEOSTIGMINE
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| Neostigmine Methylsulphate Injection Solution for injection | 🇳🇬Nigeria | Chez Resources Pharmaceutical Limited | active | Feb 2030 |
| Neostigmine Methyl Sulphate Injection Solution for injection | 🇳🇬Nigeria | Phillips Pharmaceuticals (Nigeria) Limited | active | Aug 2026 |
| STIGMINE Solution injectable / 0.5 mg/ml | 🇹🇳Tunisia | STERIPHARM | expired | Mar 2021 |
| STIGMINE Solution injectable / 0.5 mg/ml | 🇹🇳Tunisia | SAIPH | expired | Sept 2014 |
| Neostigmine Injection | 🇹🇿Tanzania | Fresenius Kabi Manufacturing SA Proprietary Limited | active | — |
| PROSTIGMINE SOLUTION INJECTABLE | 🇲🇦Morocco | — | active | — |
NEOSTIGMINE in Africa — Regulatory Overview
NEOSTIGMINE is registered across 4 African markets with 6 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Nigeria, Tunisia, Morocco, Tanzania. AfricaRegulatory refreshes this data daily from official government sources.
Of the 6 registrations, 4 (67%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.